CytomX Therapeutics Inc

NASDAQ:CTMXUnited States

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. It is advancing potential first-in-class and best-in-class antibody-based therapeutics created using its PROBODY therapeutic technology platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-904, CX-2051 and CX-801. CX-904 is a conditionally activated T-cell-engaging antibody targeting the epidermal growth factor receptor on tumor cells and the CD3 receptor on T cells and partnered with Amgen in a global co-development alliance. CX-2051 is a conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM) with potential applicability across multiple EpCAM-expressing epithelial cancers.

Contact Information

Headquarters

151 Oyster Point Blvd., Suite 400SOUTH SAN FRANCISCO, CA, United States 94080

Phone

650-515-3185

Fax

650-351-0353

Executives

Chairman of the Board, Chief Executive Officer

Sean Mccarthy

Senior Vice President, Chief Scientific Officer

Marcia Belvin

Senior Vice President, Chief Compliance Officer, General Counsel, Secretary

Lloyd Rowland

Senior Vice President, Chief Business Officer and Head of Strategy

Jeffrey Landau

Lead Independent Director

Matthew Young